Targeted radiation therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new way to find and treat liver cancer that cannot be removed by surgery. First, a special dye (RYZ811) is used to see if your cancer cells have a marker called GPC3. If they do, you may receive a targeted radiation treatment (RYZ801) that seeks out those cells. This trial is for people whose liver cancer has grown despite receiving at least one prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with hepatocellular carcinoma (HCC) – a type of liver cancer that cannot be removed with surgery.
- Your liver cancer has gotten worse after at least one previous treatment that goes through your bloodstream (like immunotherapy or targeted therapy).
- Your liver function is good (Child-Pugh class A), meaning your liver is still working well.
- You have not had a liver transplant or a procedure where tiny radioactive beads were injected into your liver.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ACE723, which is designed to specifically attack liver cancer cells while sparing healthy cells. It is for people with advanced liver cancer that has not responded to or has worsened after standard treatments that included immunotherapy.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
This trial tests a combination of radiation therapy, an immunotherapy drug called camrelizumab, and a targeted therapy pill called apatinib for people with advanced liver cancer that has spread to the main blood vessel of the liver. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
This trial tests a combination of radioactive microspheres (Yttrium-90) with targeted immunotherapy drugs (camrelizumab and apatinib) for people with liver cancer (HCC) that cannot be surgically removed. It may be an option for those with intermediate-stage disease who haven't had prior systemic therapy.
This trial tests a new combination for liver cancer that cannot be surgically removed yet. It uses tiny radioactive beads (yttrium-90) to deliver radiation directly to the tumor, along with immunotherapy drugs and a targeted therapy to shrink the tumor, with the hope that it can later be surgically removed.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.